GlassScriptPhysician profile
Deirdre J Gundy
NPI 1922082155
$3,073.81
in general payments reported to CMS, 2019-2025
24 companies · $926 in 2025
The $926 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $34.25 · 2021: $97.49 · 2022: $94.27 · 2023: $167 · 2024: $146 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,171.21 | 2019 | |
| Astellas Pharma US INC | $313.01 | 2019-2025 | Veozah |
| Sumitomo Pharma America, INC. | $189.81 | 2023-2025 | Myfembree |
| Amgen INC. | $182.77 | 2019-2024 | Evenity, Prolia |
| Exeltis, USA INC. | $170.30 | 2022-2025 | Slynd |
| Millicent US INC | $152.89 | 2024-2025 | Femlyv, Intrarosa |
| Mayne Pharma Commercial LLC | $152.06 | 2025 | |
| Abbvie INC. | $148.26 | 2019-2021 | |
| Hologic Sales and Service, LLC | $108.66 | 2019-2025 | Thinprep 2000 Processor, Novasure |
| Organon LLC | $78.05 | 2021-2023 | Nexplanon |
| Janssen Biotech, INC. | $65.48 | 2025 | Erleada |
| Merck Sharp & Dohme LLC | $61.67 | 2019-2021 | |
| Evofem Biosciences, INC. | $45.23 | 2025 | Phexxi, Solosec, Phexx |
| Pfizer INC. | $38.41 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.32 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.73 | 2019 | |
| Shield Therapeutics INC | $22.22 | 2023 | Accrufer |
| Coopersurgical, INC. | $21.41 | 2022 | |
| Antares Pharma, INC. | $21.03 | 2025 | Xyosted |
| Allergan, INC. | $19.50 | 2019 | |
| Therapeuticsmd, INC. | $17.73 | 2020 | |
| Tolmar, INC. | $17.04 | 2025 | Jatenzo |
| Boston Scientific Corporation | $16.59 | 2025 | Varithena Administration Pack |
| Amag Pharmaceuticals, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deirdre Gundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.